Conduit Pharmaceuticals has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Conduit Pharmaceuticals Inc., the registrant, indicating that no filing fee was required. This step is typically part of the process for preparing for upcoming shareholder meetings, where various corporate matters including the election of directors, approval of compensation plans, and other significant business decisions are presented for shareholder vote.

Conduit Pharmaceuticals has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement. This filing, made under Schedule 14A, is in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Conduit Pharmaceuticals Inc., the registrant, indicating that no filing fee was required. This step is typically part of the process for preparing for upcoming shareholder meetings, where various corporate matters including the election of directors, approval of compensation plans, and other significant business decisions are presented for shareholder vote.